Thank you for your interest in Synthon.
We have set up this page to share news with you about Synthon. We would like to receive your thoughts on our updates, but content provided by anyone other than Synthon does not represent the opinions or positions of Synthon.
In some cases we might need to remove your comment from our wall.
• Please refrain from mentioning Synthon products or products from other companies. As we work in regulated industries and because of the unique legal situation in the health care space, we may not engage in discussions about sensitive topics or products, ours or those of other companies, on this page.
• If your post describes possible side effects associated with a Synthon product, we may be required to get in touch with you for further information. Please contact us to report an adverse event related to Synthon products by sending an e-mail to drug.safety@synthon.com.
• Comments or posts that are factually inaccurate or misleading, are spam, inappropriate, off-topic, abusive, use profanity or contain personal information, e.g. names of individuals, e-mail addresses or phone numbers, will be deleted.
• Given the serious implications of unsolicited and unverified medical advice, any post containing medical advice will not be allowed on our page. We recommend that you consult your health care provider about personal health matters.
There may be other circumstances that require us to remove a comment. Synthon reserves the right to delete any post at its sole discretion.
We have set up this page to share news with you about Synthon. We would like to receive your thoughts on our updates, but content provided by anyone other than Synthon does not represent the opinions or positions of Synthon.
In some cases we might need to remove your comment from our wall.
• Please refrain from mentioning Synthon products or products from other companies. As we work in regulated industries and because of the unique legal situation in the health care space, we may not engage in discussions about sensitive topics or products, ours or those of other companies, on this page.
• If your post describes possible side effects associated with a Synthon product, we may be required to get in touch with you for further information. Please contact us to report an adverse event related to Synthon products by sending an e-mail to drug.safety@synthon.com.
• Comments or posts that are factually inaccurate or misleading, are spam, inappropriate, off-topic, abusive, use profanity or contain personal information, e.g. names of individuals, e-mail addresses or phone numbers, will be deleted.
• Given the serious implications of unsolicited and unverified medical advice, any post containing medical advice will not be allowed on our page. We recommend that you consult your health care provider about personal health matters.
There may be other circumstances that require us to remove a comment. Synthon reserves the right to delete any post at its sole discretion.
Location: Netherlands
Employees: 1001-5000
Phone: +31 24 372 7700
Founded date: 1991
Investors 2
| Date | Name | Website |
| - | Oost NL | oostnl.com |
| - | Aglaia Onc... | aglaia-onc... |
Mentions in press and media 8
| Date | Title | Description |
| 23.01.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 31 December 2025 with key figures for the first nine months of the 2025/2026 financial year | Positive momentum following a considerably improved market environment HBM Healthcare Investments generated a profit of CHF 191 million in the third quarter of the 2025/2026 financial year. This brings the total profit for the first nine m... |
| 18.07.2025 | BC Partners намерена продать американскую софтверную компанию Navex за $2,5 млрд | В рамках сделки Blackstone Inc. также станет миноритарным инвестором в Navex, уточнили источники, пожелавшие остаться неназванными, поскольку информация является конфиденциальной. BC Partners сохранит долю в компании и может официально объя... |
| 29.01.2025 | Jefferies Hires Tim Kerry as Co-Head of EMEA Leveraged Finance | (Bloomberg) -- Jefferies Financial Group Inc. hired Tim Kerry from Barclays Plc as the bank builds up its ranks to prepare for a wave of M&A-related financings. Kerry will join Jefferies as co-head of EMEA leveraged finance and run the ... |
| 17.12.2024 | Goldman Unit покупает фармацевтическую компанию Synthon за €2 млрд у BC Partners | BC Partners сохранит миноритарный пакет акций Synthon для поддержки будущего роста. Основанная в 1991 году, компания Synthon International разрабатывает и производит дженерики для терапевтических областей, включая онкологию, центральную нер... |
| 02.07.2019 | BC Partners to Acquire Synthon International Holding B.V. | London, 2nd July 2019 – Funds advised by BC Partners (“BC Partners”), a leading international private equity firm, have reached an agreement to acquire a majority stake in Synthon International Holding B.V. (“Synthon” or “the Company”), a g... |
| 03.03.2017 | Buyout buzz centers on a Novartis NASH deal for Genfit; Synthon joins the CD47 club | → Genfit $GNFT has become the target of the latest round of M&A rumors. StreetInsider says that Novartis is close to a deal to acquire France’s Genfit, which has been working on a new drug for NASH, now in Phase III. → You c... |
| 19.05.2011 | Generic of UCB allergy med Xyzal gets preliminary FDA approval for Synthon | Synthon said it believes it is the first to file an application with the FDA for a Xyzal generic. Being first to file gives Synthon the advantage of 180 days of marketing exclusivity over other Xyzal generics. The FDA approved Belgium-based... |
| - | Generic of UCB allergy med Xyzal gets preliminary FDA approval for Synthon | Generic drug company Synthon Pharmaceuticals has received tentative U.S. Food and Drug Administration approval on its application to make a version of UCB‘s (EBR:UCB) allergy medicine Xyzal. Netherlands-based Synthon, which has its U.S. hea... |